96 related articles for article (PubMed ID: 17695520)
1. Effect of vascular targeting agent Oxi4503 on tumor cell kinetics in a mouse model of colorectal liver metastasis.
Chan LS; Malcontenti-Wilson C; Muralidharan V; Christophi C
Anticancer Res; 2007; 27(4B):2317-23. PubMed ID: 17695520
[TBL] [Abstract][Full Text] [Related]
2. Vascular targeting agent Oxi4503 inhibits tumor growth in a colorectal liver metastases model.
Malcontenti-Wilson C; Chan L; Nikfarjam M; Muralidharan V; Christophi C
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e96-e104. PubMed ID: 17559382
[TBL] [Abstract][Full Text] [Related]
3. Alterations in vascular architecture and permeability following OXi4503 treatment.
Chan LS; Malcontenti-Wilson C; Muralidharan V; Christophi C
Anticancer Drugs; 2008 Jan; 19(1):17-22. PubMed ID: 18043126
[TBL] [Abstract][Full Text] [Related]
4. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.
Hua J; Sheng Y; Pinney KG; Garner CM; Kane RR; Prezioso JA; Pettit GR; Chaplin DJ; Edvardsen K
Anticancer Res; 2003; 23(2B):1433-40. PubMed ID: 12820406
[TBL] [Abstract][Full Text] [Related]
5. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model.
Malcontenti-Wilson C; Muralidharan V; Skinner S; Christophi C; Sherris D; O'Brien PE
Clin Cancer Res; 2001 Apr; 7(4):1052-60. PubMed ID: 11309357
[TBL] [Abstract][Full Text] [Related]
6. Changes in the microvascular architecture of colorectal liver metastases following the administration of SMANCS/lipiodol.
Kuruppu D; Christophi C; Maeda H; O'Brien PE
J Surg Res; 2002 Mar; 103(1):47-54. PubMed ID: 11855917
[TBL] [Abstract][Full Text] [Related]
7. Styrene maleic acid-pirarubicin disrupts tumor microcirculation and enhances the permeability of colorectal liver metastases.
Daruwalla J; Greish K; Malcontenti-Wilson C; Muralidharan V; Iyer A; Maeda H; Christophi C
J Vasc Res; 2009; 46(3):218-28. PubMed ID: 18953175
[TBL] [Abstract][Full Text] [Related]
8. Effect of thalidomide on colorectal cancer liver metastases in CBA mice.
Daruwalla J; Nikfarjam M; Malcontenti-Wilson C; Muralidharan V; Christophi C
J Surg Oncol; 2005 Aug; 91(2):134-40. PubMed ID: 16028287
[TBL] [Abstract][Full Text] [Related]
9. Spatial morphological and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent treatments.
Nguyen L; Fifis T; Malcontenti-Wilson C; Chan LS; Costa PN; Nikfarjam M; Muralidharan V; Christophi C
BMC Cancer; 2012 Nov; 12():522. PubMed ID: 23153292
[TBL] [Abstract][Full Text] [Related]
10. Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis.
Nguyen L; Fifis T; Christophi C
BMC Cancer; 2016 Jul; 16():533. PubMed ID: 27460820
[TBL] [Abstract][Full Text] [Related]
11. Suppression of colorectal cancer liver metastasis and extension of survival by expression of apolipoprotein(a) kringles.
Yu HK; Kim JS; Lee HJ; Ahn JH; Lee SK; Hong SW; Yoon Y
Cancer Res; 2004 Oct; 64(19):7092-8. PubMed ID: 15466205
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin inhibits hepatectomy-induced stimulation of metastatic tumor growth by reduction of angiogenesis, microvascular blood perfusion, and tumor cell proliferation.
Rupertus K; Dahlem C; Menger MD; Schilling MK; Kollmar O
Ann Surg Oncol; 2009 Sep; 16(9):2629-37. PubMed ID: 19551445
[TBL] [Abstract][Full Text] [Related]
13. Endostatin inhibits murine colon carcinoma sinusoidal-type metastases by preferential targeting of hepatic sinusoidal endothelium.
Solaun MS; Mendoza L; De Luca M; Gutierrez V; López MP; Olaso E; Lee Sim BK; Vidal-Vanaclocha F
Hepatology; 2002 May; 35(5):1104-16. PubMed ID: 11981760
[TBL] [Abstract][Full Text] [Related]
14. Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique.
Salmon HW; Mladinich C; Siemann DW
Eur J Cancer; 2006 Nov; 42(17):3073-8. PubMed ID: 16956760
[TBL] [Abstract][Full Text] [Related]
15. Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis.
Sheng Y; Hua J; Pinney KG; Garner CM; Kane RR; Prezioso JA; Chaplin DJ; Edvardsen K
Int J Cancer; 2004 Sep; 111(4):604-10. PubMed ID: 15239140
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver.
Gray MJ; Van Buren G; Dallas NA; Xia L; Wang X; Yang AD; Somcio RJ; Lin YG; Lim S; Fan F; Mangala LS; Arumugam T; Logsdon CD; Lopez-Berestein G; Sood AK; Ellis LM
J Natl Cancer Inst; 2008 Jan; 100(2):109-20. PubMed ID: 18182619
[TBL] [Abstract][Full Text] [Related]
17. Effect of blood flow occlusion on laser hyperthermia for liver metastases.
Muralidharan V; Malcontenti-Wilson C; Christophi C
J Surg Res; 2002 Apr; 103(2):165-74. PubMed ID: 11922731
[TBL] [Abstract][Full Text] [Related]
18. Progressive microvascular injury in liver and colorectal liver metastases following laser induced focal hyperthermia therapy.
Nikfarjam M; Muralidharan V; Malcontenti-Wilson C; Christophi C
Lasers Surg Med; 2005 Jul; 37(1):64-73. PubMed ID: 15954121
[TBL] [Abstract][Full Text] [Related]
19. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
20. Treatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumor.
Fifis T; Nguyen L; Malcontenti-Wilson C; Chan LS; Nunes Costa PL; Daruwalla J; Nikfarjam M; Muralidharan V; Waltham M; Thompson EW; Christophi C
Cancer Med; 2013 Oct; 2(5):595-610. PubMed ID: 24403226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
